farnesol has been researched along with Demyelinating Diseases in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, BO; Doo, HM; Hong, YB; Jang, SY; Kim, HJ; Kwak, G; Lee, YI; Park, NY | 1 |
| Aizman, E; Assaf, Y; Chapman, J; Kloog, Y; Mor, A | 1 |
2 other study(ies) available for farnesol and Demyelinating Diseases
| Article | Year |
|---|---|
Farnesol Ameliorates Demyelinating Phenotype in a Cellular and Animal Model of Charcot-Marie-Tooth Disease Type 1A.
Topics: Animals; Biomarkers; Charcot-Marie-Tooth Disease; Demyelinating Diseases; Disease Models, Animal; Disease Susceptibility; Farnesol; Female; Gene Expression; Male; Mice; Myelin Proteins; Phenotype; Schwann Cells | 2021 |
The combined treatment of Copaxone and Salirasib attenuates experimental autoimmune encephalomyelitis (EAE) in mice.
Topics: Animals; Carrier Proteins; CD3 Complex; Cell Proliferation; Cytokines; Demyelinating Diseases; Disease Models, Animal; DNA Helicases; Drug Synergism; Drug Therapy, Combination; Encephalomyelitis, Autoimmune, Experimental; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Extracellular Signal-Regulated MAP Kinases; Farnesol; Female; Forkhead Transcription Factors; Glatiramer Acetate; Immunosuppressive Agents; Leukemic Infiltration; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Peptides; Poly-ADP-Ribose Binding Proteins; RNA Helicases; RNA Recognition Motif Proteins; Salicylates; Spinal Cord; Spleen; Statistics, Nonparametric; Time Factors | 2010 |